Filing summary: Venaxis, Inc. 2013 Form 10-K
Important identity and period note: The supplied filing is for Venaxis, Inc., not Riot Platforms, Inc. It reports the fiscal year ended December 31, 2013; it is not a 2013 Q4 filing for Riot. The summary below reflects the filing actually provided.
Business context and reporting period
Venaxis was developing APPY 1, a blood-based test intended to help emergency physicians assess appendicitis risk in patients ages 2–20. Its business was focused primarily on product development and commercialization, with limited APPY 1 sales beginning in Europe. The company had CE marking in Europe but had not yet submitted its planned FDA 510(k) application. It also licensed animal-health assets to Ceva and had largely discontinued its former human-antigen business.
Financial results and liquidity
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Product sales | $56,000 | $42,000 |
| License-fee revenue recognized | $84,620 | $20,571 |
| Total revenue lines shown in the statement of operations | $140,688 | $62,128 |
| Gross profit on product sales | $34,875 | $40,965 |
| Operating expenses | $12.22 million | $9.02 million |
| Net loss | $12.15 million | $9.21 million |
| Net cash used in operating activities | $9.73 million | $5.49 million |
Product sales gross margin fell to 62% from 99%; the filing attributes the change to the different products sold and higher APPY 1 product costs. R&D expense increased 75% to $6.71 million, principally as pivotal-trial activity accelerated. SG&A rose 6% to $5.52 million. The 2013 loss per share was $0.72, versus $1.84 in 2012; the lower per-share loss reflects a substantially higher weighted-average share count, not improved net income.
At year-end, cash and cash equivalents were $5.66 million and short-term investments were $8.64 million, totaling approximately $14.30 million. Working capital was $12.51 million; total assets were $18.64 million, total liabilities $5.69 million, and stockholders’ equity $12.95 million. Debt and other obligations totaled $2.47 million, including mortgage notes of $2.30 million; the mortgage’s commercial-bank portion has a five-year balloon maturity. Operating cash burn increased from 2012. Financing cash inflow of $12.04 million included $12.97 million net proceeds from the 2013 stock offering. Cash and cash equivalents declined by $5.32 million during the year, while short-term investments increased.
Material changes versus the prior comparable period
- Revenue lines increased, with 2013 product sales from European APPY 1 initial stocking orders and higher recognized license revenue; the 2012 sales were from antigen products.
- Net loss widened by about $2.94 million, and operating cash use increased by about $4.24 million.
- R&D increased by $2.87 million as the pivotal clinical trial advanced; management expected R&D spending to decrease in 2014 after trial enrollment was completed.
- Cash and cash equivalents fell from $10.98 million to $5.66 million, while total cash and liquid investments rose from approximately $12.14 million to $14.30 million.
- Shares issued and outstanding increased from 9.95 million to 21.45 million, largely reflecting the May 2013 offering. That offering also issued warrants to purchase up to 4.025 million shares at $1.36 per share.
Outlook, risks, contingencies, and unusual items
- Management expected ongoing operating losses in the near term and said existing working capital should fund estimated needs through the remainder of 2014 and into early 2015. The company was pursuing additional financing, with no assurance it would be available on acceptable terms. Management warned that failure to obtain FDA clearance could require a change in strategy or cessation of operations.
- The pivotal study enrolled 1,887 evaluable patients and reported sensitivity of 96.9%, specificity of 37.8%, and negative predictive value of 97.3%. The company was still finalizing its FDA submission; clearance was uncertain.
- In early 2014, Venaxis signed distribution agreements covering Spain and the Benelux region. These were subsequent developments, not FY 2013 revenue performance.
- The animal-health license provides for potential milestone payments and low-double-digit royalties, subject to development, approvals, and sales; the licensee has termination rights. The former Novartis termination obligation was paid in full by year-end 2013.
- A securities class-action case was dismissed by the district court, but plaintiffs’ appeal was pending before the Tenth Circuit at the filing date. The company said it intended to continue defending the claims.
- The filing reports a $33,000 patent impairment charge in 2013. No income-tax benefit was recorded; approximately $80 million of net operating loss carryforwards were subject to a full valuation allowance.
- The independent auditor issued an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting.
Most important facts for investors to verify
- Confirm issuer identity and reporting period: this is Venaxis’s FY 2013 10-K, not a Riot Platforms filing or a standalone Q4 report.
- Check subsequent FDA developments, including whether the APPY 1 submission was filed and whether clearance was obtained.
- Assess cash burn against available liquidity and the company’s estimate that funds would last into early 2015; monitor financing needs and dilution.
- Verify whether European distributors generated meaningful sales and whether animal-health milestones or royalties were achieved.
- Track the appeal in the securities class action and review the mortgage balloon terms and share-and-warrant dilution.